Milos Brankovic1, K Martijn Akkerhuis2, Henk Mouthaan3, Alina Constantinescu2, Kadir Caliskan2, Jan van Ramshorst4, Tjeerd Germans4, Victor Umans4, Isabella Kardys5. 1. Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands; School of Medicine, University of Belgrade, Belgrade, Serbia. 2. Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands. 3. Olink Proteomics AB, Uppsala, Sweden. 4. Department of Cardiology, Noordwest Ziekenhuisgroep, Alkmaar, the Netherlands. 5. Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address: i.kardys@erasmusmc.nl.
Abstract
BACKGROUND: Our aim was to explore potential use of temporal profiles of seven emerging cardio-renal and two pulmonary candidate biomarkers for predicting future adverse clinical outcome in stable patients with chronic heart failure (CHF). METHODS: In 263 CHF patients, we determined the risk of a composite endpoint of HF-hospitalization, cardiac death, LVAD-placement and heart transplantation in relation to repeatedly assessed (567 samples in total) blood biomarker levels, and slopes of their temporal trajectories (i.e., rate of biomarker change per year). In each patient, we estimated biomarker trajectories using repeatedly measured osteopontin (OPN), osteoprotegerin (OPG), epidermal growth factor receptor (EGFR), heparin-binding protein (HBP), trefoil factor-3 (TFF3), kallikrein-6 (KLK-6), matrix extracellular phosphoglycoprotein (MEPE), pulmonary surfactant-associated protein-D (PSP-D), and secretoglobulin family 3A-member-2 (SCGB3A2). RESULTS: During 2.2 years of follow-up, OPN, OPG, and HBP levels predicted the composite endpoint (univariable hazard ratio [95% confidence interval] per 1SD increase: 2.31 [1.76-3.15], 2.23 [1.69-3.00], and 1.36[1.09-1.70]). Independently of the biomarkers' levels, the slopes of OPG, TFF-3, PSP-D trajectories were also strong clinical predictors (per 0.1SD increase: 1.24 [1.14-1.38], 1.31 [1.17-1.49], and 1.32 [1.21-1.47]). All associations persisted after multivariable adjustment for baseline characteristics, and repeatedly assessed CHF pharmacological treatment and cardiac biomarkers NT-proBNP and troponin T. CONCLUSIONS: Repeatedly-measured levels of OPN, OPG, and HBP, and slopes of OPG, TFF-3, and PSP-D strongly predict clinical outcome. These candidate biomarkers may be clinically relevant as they could further define a patient's risk and provide additional pathophysiological insights into CHF.
BACKGROUND: Our aim was to explore potential use of temporal profiles of seven emerging cardio-renal and two pulmonary candidate biomarkers for predicting future adverse clinical outcome in stable patients with chronic heart failure (CHF). METHODS: In 263 CHFpatients, we determined the risk of a composite endpoint of HF-hospitalization, cardiac death, LVAD-placement and heart transplantation in relation to repeatedly assessed (567 samples in total) blood biomarker levels, and slopes of their temporal trajectories (i.e., rate of biomarker change per year). In each patient, we estimated biomarker trajectories using repeatedly measured osteopontin (OPN), osteoprotegerin (OPG), epidermal growth factor receptor (EGFR), heparin-binding protein (HBP), trefoil factor-3 (TFF3), kallikrein-6 (KLK-6), matrix extracellular phosphoglycoprotein (MEPE), pulmonary surfactant-associated protein-D (PSP-D), and secretoglobulin family 3A-member-2 (SCGB3A2). RESULTS: During 2.2 years of follow-up, OPN, OPG, and HBP levels predicted the composite endpoint (univariable hazard ratio [95% confidence interval] per 1SD increase: 2.31 [1.76-3.15], 2.23 [1.69-3.00], and 1.36[1.09-1.70]). Independently of the biomarkers' levels, the slopes of OPG, TFF-3, PSP-D trajectories were also strong clinical predictors (per 0.1SD increase: 1.24 [1.14-1.38], 1.31 [1.17-1.49], and 1.32 [1.21-1.47]). All associations persisted after multivariable adjustment for baseline characteristics, and repeatedly assessed CHF pharmacological treatment and cardiac biomarkers NT-proBNP and troponin T. CONCLUSIONS: Repeatedly-measured levels of OPN, OPG, and HBP, and slopes of OPG, TFF-3, and PSP-D strongly predict clinical outcome. These candidate biomarkers may be clinically relevant as they could further define a patient's risk and provide additional pathophysiological insights into CHF.
Authors: Nicolas Girerd; John Cleland; Stefan D Anker; William Byra; Carolyn S P Lam; David Lapolice; Mandeep R Mehra; Dirk J van Veldhuisen; Emmanuel Bresso; Zohra Lamiral; Barry Greenberg; Faiez Zannad Journal: Sci Rep Date: 2022-05-20 Impact factor: 4.996
Authors: Daan Ceelen; Adriaan A Voors; Jasper Tromp; Dirk J van Veldhuisen; Kenneth Dickstein; Rudolf A de Boer; Chim C Lang; Stefan D Anker; Leong L Ng; Marco Metra; Piotr Ponikowski; Sylwia M Figarska Journal: Eur J Heart Fail Date: 2022-01-23 Impact factor: 17.349
Authors: Elena Vianello; Marta Kalousová; Elena Dozio; Lorenza Tacchini; Tomáš Zima; Massimiliano Marco Corsi Romanelli Journal: Int J Mol Sci Date: 2020-08-04 Impact factor: 5.923